ReviewAdvances in hematology2015
Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.
Review in Advances in hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Testicular aggressive B-cell lymphoma with plasmablastic morphology harboring concurrent IGH::MYC and IGH::BCL2 rearrangements.Journal of hematopathology · 2026Article
- Duodenal plasmablastic lymphoma in an human immunodeficency virus-negative patient: a case report.Journal of medical case reports · 2023Review
- HIV/AIDS Associated Lymphoma: Review.Blood and lymphatic cancer : targets and therapy · 2022Review
- Atypical presentation of plasmablastic lymphoma in immunocompetent patient.BMJ case reports · 2021Article
- Crohn's Disease Accompanied with Small Intestinal Extramedullary Plasmacytoma.Internal medicine (Tokyo, Japan) · 2019Article
- Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis.Case reports in hematology · 2019Article
- Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets.Scientific reports · 2017Article
- Plasmablasticlike lymphoma arising within chronic pyoderma gangrenosum.JAAD case reports · 2017Article
- Oral plasmablastic lymphoma as the first manifestation of AIDS.Anais brasileiros de dermatologia · 2017Article
- Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature.Diagnostic pathology · 2016Review
- Gingival fibromatosis: clinical, molecular and therapeutic issues.Orphanet journal of rare diseases · 2016Review
- Retracted: Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.Advances in hematology · 2016Article
- What is that? HIV-negative plasmablastic lymphoma with intramuscular masses.BJR case reports · 2016Article
- Non-Hodgkin's Plasmablastic Lymphoma as Initial Presentation of Human Immunodeficiency Virus.Journal of investigative medicine high impact case reportsArticle
- Solitary Primary Central Nervous System Plasmablastic Lymphoma in a Young Immunocompetent Female: Report on an Extremely Rare Entity with Review of Literature.Asian journal of neurosurgeryArticle
Corrections and comments
- Retraction · 2016-03-24Euphemisms for Plagiarism · Plagiarism of Text ·
- Retracted
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM). PBL is also a therapeutic challenge with a clinical course characterized by a high rate of relapse and death. There is no standard chemotherapy protocol for treatment of PBL. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens have been the backbone while more intensive regimens such as cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, high-dose cytarabine (CODOX-M/IVAC), or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) are possible options. Recently, a few studies have reported the potential value of the proteasome inhibitor bortezomib and thalidomide in PBL patients. The introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs) and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials. The aim of this paper is to review the recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and outcome in patients with PBL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.